Medtronic VenaSeal Closure System Demonstrates Long-Term Durability and Improved Quality of Life in Patients with Venous Reflux Disease

Medtronic Unveils Data for VenaSeal Closure System at Charing Cross and the International Vein Congress

DUBLIN., This week at the 2016 Charing Cross Symposium in London and the International Vein Congress in Miami, Medtronic plc  unveiled clinical data for the VenaSeal^(TM) closure system demonstrating consistent long-term durability and improved quality of life in patients with venous reflux disease. The new data presented included two-year outcomes from the VeClose pivotal clinical study, with two additional subanalyses evaluating quality of life and physician ease-of-use; and three-year results from the European Sapheon Closure System Observational ProspectivE (eSCOPE) study.

VenaSeal is a non-tumescent, non-thermal, non-sclerosant procedure that uses a proprietary medical adhesive to close superficial veins of the lower extremities, such as the great saphenous vein (GSV), in patients with symptomatic venous reflux.

"As shown by our unmatched body of Level 1 evidence in the venous industry, Medtronic has demonstrated its deep-rooted commitment to providing clinically-proven and patient friendly treatment options for patients with chronic venous insufficiency," said Sandra Lesenfants, vice president and general manager of the endoVenous business in Medtronic's Aortic and Peripheral Vascular division. "We're enthusiastic about the unveiling of such strong datasets, and we look forward to continuing to build upon this clinical program."

Source: Medtronic plc